KR101627605B1 - 염증성 장애 치료용 조성물 및 방법 - Google Patents

염증성 장애 치료용 조성물 및 방법 Download PDF

Info

Publication number
KR101627605B1
KR101627605B1 KR1020127014048A KR20127014048A KR101627605B1 KR 101627605 B1 KR101627605 B1 KR 101627605B1 KR 1020127014048 A KR1020127014048 A KR 1020127014048A KR 20127014048 A KR20127014048 A KR 20127014048A KR 101627605 B1 KR101627605 B1 KR 101627605B1
Authority
KR
South Korea
Prior art keywords
antibody
seq
fragment
artificial sequence
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127014048A
Other languages
English (en)
Korean (ko)
Other versions
KR20120104560A (ko
Inventor
미유키 니시무라
요시마사 사카모토
데쓰 가와노
도시오 이마이
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43922220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101627605(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20120104560A publication Critical patent/KR20120104560A/ko
Application granted granted Critical
Publication of KR101627605B1 publication Critical patent/KR101627605B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020127014048A 2009-10-30 2010-10-28 염증성 장애 치료용 조성물 및 방법 Active KR101627605B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25652109P 2009-10-30 2009-10-30
US61/256,521 2009-10-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167014386A Division KR102099596B1 (ko) 2009-10-30 2010-10-28 염증성 장애 치료용 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20120104560A KR20120104560A (ko) 2012-09-21
KR101627605B1 true KR101627605B1 (ko) 2016-06-07

Family

ID=43922220

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127014048A Active KR101627605B1 (ko) 2009-10-30 2010-10-28 염증성 장애 치료용 조성물 및 방법
KR1020167014386A Active KR102099596B1 (ko) 2009-10-30 2010-10-28 염증성 장애 치료용 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167014386A Active KR102099596B1 (ko) 2009-10-30 2010-10-28 염증성 장애 치료용 조성물 및 방법

Country Status (33)

Country Link
US (1) US8932592B2 (https=)
EP (1) EP2493930B1 (https=)
JP (2) JP5631991B2 (https=)
KR (2) KR101627605B1 (https=)
CN (1) CN102597003B (https=)
AR (2) AR078796A1 (https=)
AU (1) AU2010312408B2 (https=)
BR (1) BR112012010266A2 (https=)
CA (1) CA2778895C (https=)
CL (2) CL2012001143A1 (https=)
CY (1) CY1121167T1 (https=)
DK (1) DK2493930T3 (https=)
ES (1) ES2698389T3 (https=)
HR (1) HRP20181973T1 (https=)
HU (1) HUE041952T2 (https=)
IL (1) IL219470A (https=)
JO (1) JO3437B1 (https=)
LT (1) LT2493930T (https=)
MX (1) MX2012005052A (https=)
MY (1) MY158481A (https=)
NZ (1) NZ599779A (https=)
PE (1) PE20121645A1 (https=)
PH (1) PH12012500828A1 (https=)
PL (1) PL2493930T3 (https=)
PT (1) PT2493930T (https=)
RS (1) RS58142B1 (https=)
RU (1) RU2569109C2 (https=)
SI (1) SI2493930T1 (https=)
SM (1) SMT201800637T1 (https=)
TW (1) TWI414308B (https=)
UA (1) UA105073C2 (https=)
WO (1) WO2011052799A1 (https=)
ZA (1) ZA201203002B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9415118B2 (en) * 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
JP6668345B2 (ja) 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
EP3159007A1 (en) 2015-10-19 2017-04-26 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating rheumatoid arthritis
JP2017154975A (ja) * 2016-02-29 2017-09-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 クローン病を治療するための医薬組成物
JP2018070473A (ja) * 2016-10-26 2018-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 関節リウマチを治療するための医薬組成物
JP2018177701A (ja) * 2017-04-14 2018-11-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 クローン病を治療するための医薬組成物
US20220196674A1 (en) * 2019-04-17 2022-06-23 Abdolamir Landi Treatment of autoimmune liver disease
US20220205980A1 (en) * 2019-04-23 2022-06-30 Eisai R&D Management Co., Ltd. Biomarker for rheumatoid arthritis treatment
KR20220110827A (ko) * 2019-12-09 2022-08-09 알렉시온 파마슈티칼스, 인코포레이티드 시신경척수염 스펙트럼 장애의 치료를 위한 항-c5 항체
CN113087795B (zh) * 2019-12-23 2025-06-10 上海普铭生物科技有限公司 针对趋化因子cx3cl1的抗体及其应用
EP4238578A4 (en) 2020-10-30 2024-09-11 Eisai R&D Management Co., Ltd. PHARMACEUTICAL COMPOSITION
CN121537534B (zh) * 2026-01-22 2026-04-07 华中科技大学同济医学院附属协和医院 靶向cx3cl1的嵌合抗原受体-巨噬细胞及在gjb2突变相关遗传性耳聋治疗中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060406A1 (en) 2000-02-18 2001-08-23 Millennium Pharmaceuticals, Inc. Therapeutic methods that target fractalkine or cx3cr1
US20020192212A1 (en) 2001-03-19 2002-12-19 Toshio Imai Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6114507A (en) 1995-06-30 2000-09-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
US6096312A (en) 1995-06-30 2000-08-01 Mochida Pharmaceutical Co., Ltd. Agent for suppressing a reduction of CD4+ lymphocytes
CN1196733A (zh) * 1995-06-30 1998-10-21 持田制药株式会社 抗Fas配体抗体和利用抗Fas配体抗体的测定方法
AU1825097A (en) 1996-01-24 1997-08-20 Schering Corporation Mammalian cx3c chemokine genes
US6548654B1 (en) 1996-01-24 2003-04-15 Schering Corporation DNA encoding mammalian CX3C chemokine genes
US7115379B1 (en) 1996-01-24 2006-10-03 Schering Corporation Anti-mammalian CX3C cytokine antibodies
US6566503B2 (en) 1996-01-24 2003-05-20 Schering Corporation Mammalian CX3C chemokine
EP0966484A4 (en) 1996-05-07 2002-04-17 Millennium Pharm Inc NEUROTACTIN AND APPLICATIONS THEREOF
US6043086A (en) 1996-05-07 2000-03-28 Millenium Biotherapeutics, Inc. Neurotactin and uses therefor
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
WO2000011950A1 (en) 1998-08-31 2000-03-09 Oregon Health Science University Prevention of cell migration initiation with cmv us28 receptor antagonists
JP2001218581A (ja) 1999-11-30 2001-08-14 Eisai Co Ltd モノクローナル抗体の作製法
US6677321B1 (en) 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
US8647612B2 (en) 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
JP4263391B2 (ja) * 2001-03-19 2009-05-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ｃｘ３ｃｒ１抗体、抗フラクタルカイン抗体及びフラクタルカインの利用
SE0101082D0 (sv) 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
ES2330731T3 (es) 2001-08-30 2009-12-15 Chemocentryx, Inc. Compuestos biciclicos como inhibidores de la union de quimioquina a us28.
WO2004041285A1 (en) 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
TWI306458B (en) * 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
EP1520586A1 (en) 2003-09-30 2005-04-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibition of fractalkine or of its receptor for the treatment of atopic allergic diseases
WO2005032589A1 (ja) * 2003-10-02 2005-04-14 Japan Science And Technology Agency Ｇｖｈｄの予防及び治療
EP1675862A1 (en) 2003-10-07 2006-07-05 AstraZeneca AB New 2-substituted, 4-amino-thiazolo 4,5-d pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
EP1806145B1 (en) * 2004-10-29 2017-08-16 Eisai R&D Management Co., Ltd. Remedy for inflammatory diseases
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
WO2008052108A2 (en) 2006-10-26 2008-05-02 Centocor Ortho Biotech Inc. Methods for use in human-adapting monoclonal antibodies
ES3006441T3 (en) * 2007-09-14 2025-03-18 Amgen Inc Homogeneous antibody populations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060406A1 (en) 2000-02-18 2001-08-23 Millennium Pharmaceuticals, Inc. Therapeutic methods that target fractalkine or cx3cr1
US20020192212A1 (en) 2001-03-19 2002-12-19 Toshio Imai Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Immunol. 159: 3613-3621(1997)

Also Published As

Publication number Publication date
KR102099596B1 (ko) 2020-04-10
LT2493930T (lt) 2019-01-10
JP2015027304A (ja) 2015-02-12
EP2493930A4 (en) 2013-12-04
MY158481A (en) 2016-10-14
NZ599779A (en) 2014-03-28
ZA201203002B (en) 2013-06-26
RS58142B1 (sr) 2019-02-28
CN102597003A (zh) 2012-07-18
RU2012122203A (ru) 2013-12-10
CA2778895C (en) 2018-08-07
AU2010312408A1 (en) 2012-06-21
HRP20181973T1 (hr) 2019-01-25
KR20120104560A (ko) 2012-09-21
AR078796A1 (es) 2011-12-07
SI2493930T1 (sl) 2018-12-31
TW201127401A (en) 2011-08-16
US20120213799A1 (en) 2012-08-23
RU2569109C2 (ru) 2015-11-20
CL2012001143A1 (es) 2012-10-05
EP2493930B1 (en) 2018-09-19
JO3437B1 (ar) 2019-10-20
ES2698389T3 (es) 2019-02-04
WO2011052799A1 (en) 2011-05-05
CN102597003B (zh) 2016-03-23
SMT201800637T1 (it) 2019-01-11
HUE041952T2 (hu) 2019-06-28
PH12012500828A1 (en) 2013-01-07
PE20121645A1 (es) 2012-12-06
PT2493930T (pt) 2018-11-29
MX2012005052A (es) 2012-05-29
AU2010312408B2 (en) 2015-07-09
PL2493930T3 (pl) 2019-03-29
JP5631991B2 (ja) 2014-11-26
EP2493930A1 (en) 2012-09-05
KR20160066055A (ko) 2016-06-09
CY1121167T1 (el) 2020-05-29
IL219470A0 (en) 2012-06-28
AR109533A2 (es) 2018-12-19
CA2778895A1 (en) 2011-05-05
CL2015000114A1 (es) 2015-04-10
UA105073C2 (uk) 2014-04-10
JP2013509158A (ja) 2013-03-14
IL219470A (en) 2017-10-31
DK2493930T3 (en) 2018-12-17
US8932592B2 (en) 2015-01-13
TWI414308B (zh) 2013-11-11
BR112012010266A2 (pt) 2016-12-06

Similar Documents

Publication Publication Date Title
KR101627605B1 (ko) 염증성 장애 치료용 조성물 및 방법
JP6529552B2 (ja) Ｃｓｆ１ｒに結合する抗体
CN101809035B (zh) 能结合胸腺基质淋巴细胞生成素的抗原结合蛋白
CN103068848B (zh) 抗N3pGlu淀粉样蛋白BETA肽抗体及其用途
JP6141834B2 (ja) 治療抗体
US20120282254A1 (en) Cd127 binding proteins
MX2010012142A (es) Anticuerpos para receptor de productos finales de glucacion avanzada (rage) y usos de los mismos.
JP6236478B2 (ja) 血清アミロイドｐ成分に特異的な抗原結合タンパク質
TW202229340A (zh) 多特異性抗體及抗體組合
HK1174041A (en) Improved anti human fraktalkine antibodies and uses thereof
HK1174041B (en) Improved anti human fraktalkine antibodies and uses thereof
WO2011080050A2 (en) Binding molecules

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120530

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150804

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20150804

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151218

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20160226

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160530

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20160531

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20160601

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20190524

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20190524

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20200521

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20200521

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20210521

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20210521

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20220520

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20220520

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20230522

Start annual number: 8

End annual number: 8